ASX RELEASE
22 September 2020
KAZIA ENTERS CLINICAL COLLABORATION WITH
DANA-FARBER CANCER INSTITUTE FOR PRIMARY CNS LYMPHOMA
Sydney, 22 September 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an
Australian oncology-focused biotechnology company, is pleased to announce that it has
entered into a collaboration with Dana-Farber Cancer Institute (DFCI) in the United States,
to investigate the use of Kazia’s investigational new drug, paxalisib (formerly GDC-0084), in
primary central nervous system (CNS) lymphoma, a potential new indication for the drug.
Key Points
• Lymphoma is a cancer of white blood cells. It occurs in the lymphatic system and can
spread almost anywhere in the body; primary CNS lymphoma (PCNSL) occurs
exclusively in the brain and central nervous system
• The PI3K inhibitor class is well validated in lymphoma outside the brain; three of the
four FDA-approved PI3K inhibitors are treatments for forms of lymphoma, but they
are assumed ineffective for PCNSL since they cannot cross the blood-brain barrier
• DFCI will initiate an open-label phase II clinical trial of paxalisib in PCNSL
• The study is expected to recruit up to 25 patients, taking up to 2 years to complete
• Kazia will provide support including study drug and a financial grant
• This study will be the sixth ongoing clinical trial of paxalisib in brain cancer
Dana-Farber Cancer Institute (DFCI) is a world-leading cancer treatment and research
centre, based in Boston, Massachusetts. It is a principal teaching affiliate of Harvard Medical
School and has been designated a Comprehensive Cancer Center by the US National Cancer
Institute. DFCI participates in as many as 600 clinical trials at any given time and has been an
important contributor to the development of many important new cancer therapies.
Kazia CEO, Dr James Garner, commented, “this is an exciting new opportunity for the
paxalisib program. We are delighted to support the team at Dana-Farber to explore the
potential for paxalisib to benefit patients with PCNSL. Dana-Farber is one of the world’s
leading centres of excellence in this disease, so we are immensely fortunate to be working
with them. We are pleased also to see a new and important target added to the broader
paxalisib clinical program, and we look forward to seeing the project commence.”
Bladerunner
